NASDAQ:CNTN Hillstream Biopharma Q4 2025 Earnings Results & Report $2.11 +0.03 (+1.44%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.12 +0.01 (+0.24%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Hillstream Biopharma reported Q4 2025 earnings on March 31, 2026. The company reported EPS of $0.54. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 31, 2026TimeBefore Market Opens Hillstream Biopharma EPS ResultsActual EPS$0.54Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AHillstream Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Hillstream Biopharma Q4 2025 Earnings FAQ Did Hillstream Biopharma beat earnings estimates for Q4 2025? Hillstream Biopharma (NASDAQ:CNTN) reported earnings of $0.54 per share for Q4 2025. The report was announced on Tuesday, March 31, 2026. Hillstream Biopharma Earnings HeadlinesHillstream Biopharma (NASDAQ:CNTN) Shares Down 8% - Time to Sell?October 9 at 2:21 AM | americanbankingnews.comCanton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational ResultsAugust 14, 2026 | prnewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 11 at 1:00 AM | Stansberry Research (Ad)Canton Strategic: Highly Intriguing Blockchain Treasury With Tangible RisksAugust 6, 2026 | seekingalpha.comThree New Directors Elected to the Board of Canton Strategic Holdings, Inc.July 28, 2026 | prnewswire.comCanton Strategic Holdings, Inc. Announces Sale of Gravitas Life Sciences, LLCJuly 23, 2026 | prnewswire.comSee More Hillstream Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hillstream Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hillstream Biopharma and other key companies, straight to your email. Email Address About Hillstream BiopharmaHillstream Biopharma (NASDAQ:CNTN), Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company’s research centers on ferroptosis, a form of regulated cell death that may offer a way to selectively target tumor cells, including cancer cells that have developed resistance to existing therapies. Hillstream’s pipeline has included HSB-1216, an investigational ferroptosis-inducing therapy being evaluated for potential use in solid tumors. The company has also pursued additional preclinical oncology programs designed to address treatment-resistant cancers. Its products remain investigational and require successful clinical development and regulatory review before they can be marketed. Hillstream Biopharma was founded to advance therapies based on discoveries in cancer biology and has operated as a U.S.-based biotechnology company. Information about its commercial operations and geographic reach is limited because the company remains focused primarily on research and clinical development rather than selling approved products.View Hillstream Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
